Results 71 to 80 of about 79,614 (239)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy

Biologics: Targets & Therapy, 2020
Miguel J Franquiz,1,2 Nicholas J Short2 1Baylor College of Medicine, Houston, TX, USA; 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Nicholas J ShortDepartment of Leukemia, The University of ...
Franquiz MJ, Short NJ
doaj  

Use of the osmolal gap in diagnosing mixed physiology hyponatremia in a child with B‐cell acute lymphoblastic leukemia

Clinical Case Reports, 2023
Key Clinical Message Hyponatremia is common among children undergoing treatment for hematologic malignancies and may be attributed to multiple underlying causes.
Jonathan M. Gabbay, Andrew E. Place, Maya Ilowite, Jia Zhu   +3 more
doaj   +1 more source

Differentiating reactive and neoplastic gamma‐delta (γδ) T‐cell expansions in the peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract The clinical and immunophenotypic attributes of reactive γδ T‐cell expansions are less well characterized than their malignant counterparts, which can pose diagnostic challenges. This study aims to investigate the characteristics and long‐term clinical outcomes of reactive γδ T‐cell expansions.
Hamza Tariq, Zubair Ilyas, Lucy Fu, Yijie Liu, Qing Ching Chen, Kristy Wolniak, Yi‐Hua Chen   +6 more
wiley   +1 more source

Mathematical Modeling of Leukemia Chemotherapy in Bone Marrow [PDF]

arXiv, 2022
Acute Lymphoblastic Leukemia (ALL) accounts for the 80% of leukemias when coming down to pediatric ages. Survival of these patients has increased by a considerable amount in recent years. However, around 15-20% of treatments are unsuccessful. For this reason, it is definitely required to come up with new strategies to study and select which patients ...
arxiv  

Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

bioRxiv, 2023
Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in bone marrow/blood (BCP acute lymphoblastic leukemia, BCP-ALL) or less common in extramedullary tissue (BCP lymphoblastic lymphoma, BCP-LBL).
E. Kroeze, I. Iaccarino, Michelle M Kleisman, Mayukh Mondal, T. Beder, M. Khouja, Marc P Hoeppner, M. Scheijde-Vermeulen, Lennart A Kester, Monika Brüggemann, C. Baldus, Gunnar Cario, R. Bladergroen, Nathalie Garnier, A. Attarbaschi, J. Verdú-Amorós, Rosemary Sutton, Elizabeth Macintyre, Kenneth Scholten, Laura Arias Padilla, Birgit Burkhardt, A. Beishuizen, M. D. den Boer, Roland P Kuiper, Jan L C Loeffen, J. Boer, W. Klapper   +26 more
semanticscholar   +1 more source

Immunophenotypic features of bone marrow tumor cell in Burkitt lymphoma/leukemia: B-lineage acute lymphoblastic leukemia diagnostics opportunities

Онкогематология, 2017
Bone marrow tumor blasts immunophenotyping is an essential part of Burkitt lymphoma/leukemia (BL) and B-cell precursor acute lymphoblastic leukemia (BCP-ALL) differential diagnostics.
I. A. Demina, T. Yu. Verzhbitskaya, S. A. Kashpor, S. A. Plyasunova, M. E. Dubrovina, L. G. Fechina, N. V. Myakova, E. V. Samochatova, A. A. Maschan, A. M. Popov   +9 more
doaj   +1 more source

A Systematic Review of Synthetic and Anticancer and Antimicrobial Activity of Quinazoline/Quinazolin‐4‐one Analogues

ChemistryOpen, EarlyView.
Quinazoline represents an important class of heterocycles with diverse medicinal and pharmacological significance. This review systematically examines scholarly efforts toward understanding different synthetic pathways emphasizing the role of metal and non‐metal catalysts including some miscellaneous reagents employed in the synthesis of quinazoline ...
Neha Manhas, Gobind Kumar, Sanjeev Dhawan, Talent Makhanya, Parvesh Singh   +4 more
wiley   +1 more source

CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy

VIEW, EarlyView.
Abstract Immuno‐oncology represents an emerging field that has significantly transformed tumor therapeutics, with immune cells serving as the cellular foundations of cancer immunotherapy. Due to its high efficiency and sensitivity, CRISPR/Cas9 genome editing is a highly promising technique for precise and rapid gene modification.
Yuhui Ma, Junxin Chen, Yuan Du, Zhihao Cao, Weizhi Ji, Yuyu Niu, Zebin Yang   +6 more
wiley   +1 more source

Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia [PDF]

arXiv, 2023
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced ...
arxiv  

In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B‐cell lymphoma (DLBCL) cell lines with different levels of expression of CD20

British Journal of Haematology, EarlyView.
Summary Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B‐cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ...
Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Adam Wright, Sandrine Jayne, Martin J. S. Dyer, Harriet S. Walter   +6 more
wiley   +1 more source